Gastrointestinal Associates, PC, Knoxville, TN.
J Clin Gastroenterol. 2024;58(5):471-474. doi: 10.1097/MCG.0000000000001884. Epub 2023 Jun 27.
We analyzed if the predictive value of multitarget stool-based DNA (mt-sDNA) varied when patients had pre-existing known colorectal cancer (CRC) risk factors.
mt-sDNA test is approved for CRC screening in average-risk patients. Whether patients with a personal history of adenomatous colon polyps or a family history of CRC (CRC risk factors) benefit from mt-sDNA testing is unknown.
We reviewed charts for all positive mt-sDNA referrals between 2017 and 2021. Diagnostic colonoscopy adherence rates were calculated. In those who had colonoscopy, we compared detection rates for any colorectal neoplasia (CRN), multiple (3 or more) adenomas, sessile serrated polyps (SSP), advanced CRN, and CRC between patients with and without known CRC risk factors.
Of 1297 referrals for positive mt-sDNA, 1176 (91%) completed a diagnostic colonoscopy. The absence of neoplasia was noted in 27% of colonoscopy exams. When neoplasia was identified, findings were as follows: any CRN (73%), multiple adenomas (34%), SSP (23%), advanced CRN (33%), and CRC (2.5%). One or more CRC risk factors were present in 229 (19%) of cases. In the CRC risk factor subgroup, patients having a prior history of adenomatous polyps or a family history of CRC were no more likely to have any CRN, multiple adenomas, SSP, advanced CRN, or CRC compared to average-risk patients when mt-sDNA was positive.
In this real-world analysis of positive mt-sDNA referrals, adherence to subsequent diagnostic colonoscopy recommendations was high. The presence of pre-existing CRC risk factors did not affect the positive predictive value of mt-sDNA.
我们分析了在患者存在已知结直肠癌(CRC)危险因素的情况下,多靶标粪便 DNA(mt-sDNA)的预测价值是否存在差异。
mt-sDNA 检测法被批准用于一般风险患者的 CRC 筛查。患有腺瘤性结肠息肉病史或 CRC 家族史(CRC 危险因素)的患者是否受益于 mt-sDNA 检测尚不清楚。
我们回顾了 2017 年至 2021 年间所有阳性 mt-sDNA 转介的图表。计算了诊断性结肠镜检查的依从率。在接受结肠镜检查的患者中,我们比较了有和无已知 CRC 危险因素的患者中任何结直肠肿瘤(CRN)、多个(3 个或更多)腺瘤、无蒂锯齿状息肉(SSP)、进展期 CRN 和 CRC 的检出率。
在 1297 例 mt-sDNA 阳性转介中,有 1176 例(91%)完成了诊断性结肠镜检查。结肠镜检查中有 27%未发现肿瘤。当发现肿瘤时,结果如下:任何 CRN(73%)、多个腺瘤(34%)、SSP(23%)、进展期 CRN(33%)和 CRC(2.5%)。有一个或多个 CRC 危险因素的患者有 229 例(19%)。在 CRC 危险因素亚组中,mt-sDNA 阳性时,与一般风险患者相比,有腺瘤性息肉病史或 CRC 家族史的患者更不可能有任何 CRN、多个腺瘤、SSP、进展期 CRN 或 CRC。
在这项针对阳性 mt-sDNA 转介的真实世界分析中,对后续诊断性结肠镜检查建议的依从性很高。存在先前存在的 CRC 危险因素并不影响 mt-sDNA 的阳性预测值。